Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The incidence of progression of diabetic retinopathy during pregnancy is unknown and its proper management uncertain. In this study, 55 insulin-dependent diabetic patients under strict glucose control were followed throughout pregnancy with serial retinal examinations by ophthalmoscopy and photographs. Nineteen patients had minimal or background retinopathy and 7 had untreated proliferative changes. Six patients had been treated before pregnancy with photocoagulation for proliferative retinopathy. A positive correlation was found between progressive proliferative diabetic retinopathy and the duration of diabetes mellitus independent of glucose control. During gestation 3 of 19 patients (16%) with minimal or background retinopathy and 6 of 7 patients (86%) with untreated proliferative retinopathy experienced deterioration of their eye disease. In 4 patients with proliferative retinopathy, progression of retinal disease was arrested with photocoagulation during pregnancy. Only 1 of 6 who had received laser treatment prior to pregnancy experienced progression of her retinopathy. These results suggest that photocoagulation prior to pregnancy may protect against rapidly progressive proliferative retinopathy and that aggressive treatment during pregnancy can prevent progression of proliferative retinopathy and visual impairment.
 ...
PMID:Effect of pregnancy on diabetic retinopathy. 720 May 95

The combination of unilateral proliferative diabetic retinopathy (PDR) in one eye and nonproliferative diabetic retinopathy (NPDR) in the fellow eye was observed in 10.1% of patients with PDR. Most patients were between the ages of 50 and 70 years; the majority had adultonset diabetes mellitus. Unilateral aphakia and anisometropia of greater than 1 diopter were both infrequently seen. The incidence of glaucoma was unremarkable. Unilateral elevated-but not necessarily abnormal-intraocular pressure was found in a significantly larger proportion of eyes with NPDR (20%) than with PDR (12%). Most patients had moderate to severe angiopathy or exudation in the eye with NPDR and modest PDR in the fellow eye; however, one third had moderate to severe PDR. In only 2% of the patients was visual acuity less than 20/200 on initial examination.
 ...
PMID:Unilateral proliferative diabetic retinopathy. I. Initial findings. 725 5

Diabetic retinopathy can be expected to progress during the term of pregnancy. A retrospective study indicated that photocoagulation was successful in preserving vision in 70 to 80% of 30 pregnant diabetic patients as well as in a similar group of nonpregnant patients with juvenile-onset diabetes. Proliferative diabetic retinopathy, in and of itself, is not an absolute indication for therapeutic abortion.
 ...
PMID:Pregnancy and diabetic retinopathy. 742 49

Intercellular adhesion molecule 1 (ICAM-1) is a member of the immunoglobulin superfamily with important functions in immune activation and inflammation. Its interaction with different cytokines [interleukin 1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma)] is important for lymphocyte migration into inflammatory sites. We used a sandwich enzyme immunoassay (EIA) for the quantitative determination of soluble ICAM-1 (cICAM-1) in vitreous and plasma from patients undergoing vitrectomy for a variety of proliferative vitreoretinal disorders. The values obtained were compared with the total vitreal protein. The respective concentrations of cICAM-1 in vitreous were as follows control samples, 3.47 +/- 1.84 ng/ml; proliferative diabetic retinopathy (PDR) of diabetes type I 27.43 +/- 14.72 ng/ml; PDR of diabetes type II, 32.46 +/- 10.31 ng/ml; idiopathic proliferative vitreoretinopathy 35.74 +/- 15.30 ng/ml; and traumatic PVR, 45.23 +/- 24.24 ng/ml. Plasma samples yielded the following concentrations: controls, 415 +/- 43.4 ng/ml; PDR of diabetes type I, 469 +/- 96.9 ng/ml; PDR of diabetes type II, 425 +/- 65.4 ng/ml; idiopathic PVR, 402 +/- 119.9 ng/ml; and traumatic PVR, 434 +/- 118.6 ng/ml. Our results demonstrate high levels of ICAM-1 in most proliferative vitreoretinal disorders. In PDR and in traumatic PVR, cICAM-1 levels were elevated significantly more than were total vitreal protein levels. In traumatic PVR, patients with a short interval between previous surgery or traumatic event demonstrated the highest levels of cICAM. Since plasma levels were not significantly altered, we suggest that local cICAM-1 production, possibly from macrophages, may be of importance in the early phase of PVR and PDR by enhancing immune activation and inflammation.
 ...
PMID:Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders. 749 36

Vitronectin, an integrin-binding a-1-glycoprotein with potent cell-adhesion and proliferation-mediating properties, has been shown to be incorporated in surgically removed membranes from patients with proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR) and macular pucker. Therefore we developed an ELISA technique to quantify levels of vitronectin in human vitreous and plasma samples in order to be able to evaluate the significance of vitronectin in these different vitreoretinal diseases. Our results indicate a significant increase of vitronectin in all proliferative disorders except idiopathic macular pucker. Adjustment of all probes to equal total protein content yielded a significant increase only in PDR (type II diabetes). Plasma samples demonstrated a significant increase of vitronectin in patients with type II diabetes suffering from PDR. Therefore, break-down of the blood-retina barrier appears to be the most likely explanation for the increased levels of vitronectin in the vitreous. Our results indicate that vitronectin may not only be involved in the regulation of epiretinal membrane formation at significantly higher levels in patients with type II diabetes, but the increase of vitronectin in diabetic plasma may also help to explain the pathological alteration of the coagulation cascade in diabetics.
 ...
PMID:The significance of vitronectin in proliferative diabetic retinopathy. 752 58

Lp(a) has atherogenic and thrombotic properties and is considered to be a major risk factor for the development of atherosclerotic disease. The risk of cardiovascular disease is increased in both insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), and Lp(a) has attracted attention as a potential risk factor in diabetic patients. Lp(a) levels are "probably" elevated in IDDM patients and related to altered metabolic control and increased urinary albumin excretion rate or renal insufficiency, although results are controversial. There appears to be a real difference between the Lp(a) of patients with proliferative diabetic retinopathy and those with or without background retinopathy. The plasma Lp(a) level may therefore be associated with microangiopathy in some IDDM patients. However, data relating Lp(a) to complications of diabetes are limited, and the literature is conflicting. The few available data suggest that Lp(a) is not elevated in NIDDM patients and that there is no strong link between blood glucose control and plasma Lp(a). There is no clear evidence as to whether Lp(a) is related to microalbuminuria in NIDDM patients. There is little evidence for a correlation between increased risk of cardiovascular disease and plasma Lp(a) among diabetic patients. However, some diabetic patients with coronary heart disease have elevated plasma Lp(a), which seems to be correlated with genetic factors (especially the isoforms of apolipoprotein a) rather than to diabetes per se. Lp(a) synthesis and catabolism could be influenced by insulin or by diabetes and its metabolic concomitants. The atherogenic and thrombogenic potential of Lp(a) could also be increased in diabetic patients. Plasma Lp(a) should be measured for both IDDM and NIDDM patients. If the Lp(a) level is elevated, it seems reasonable to check the other major vascular risk factors.
 ...
PMID:[Lipoprotein (a) and diabetes mellitus]. 762 73

Diabetic retinopathy (DR), an ocular complication of diabetes mellitus, is the leading cause of blindness in Americans age 20 to 74 today. The more severe stage of the disease, proliferative diabetic retinopathy, affects an estimated 700,000 Americans. Based on clinical findings, the disease is generally classified as nonproliferative DR or proliferative DR. While the former often begins as a symptomatically silent disease, it nevertheless may be progressing to itself cause significant visual loss. Based principally on evidence from several studies sponsored by the National Eye Institute, current treatment consists of regular observation by an ophthalmologist, laser photocoagulation, and vitrectomy. In addition, preventive methods such as tight glycemic control and ophthalmic screening of diabetics appear beneficial. While the ophthalmologist can provide specialized services for the DR patient, prevention and control lie largely in the hands of the primary care physician. Thus, only when primary and specialized care have established a strong partnership can they save the sight of the thousands at risk for diabetic retinopathy.
 ...
PMID:Managing diabetic retinopathy: the partnership between ophthalmologist and primary care physician. 767 96

1. Within 15 to 20 years of being diagnosed as having diabetes mellitus, 90% of patients will have some degree of diabetic retinopathy and 25% will have proliferative diabetic retinopathy. 2. The majority of the cases of blindness from diabetic retinopathy could be prevented or significantly delayed by timely and appropriate management of diabetic retinopathy. 3. Until a cure for diabetes mellitus is discovered, all patients with diabetes mellitus should receive ophthalmic evaluation soon after the diagnosis is made.
 ...
PMID:Ocular manifestations of diabetes mellitus (continuing education credit). 779 55

We retrospectively reviewed the eyes of 143 patients with tractional retinal detachment caused by diabetes that had been studied biomicroscopically, and, after some exclusions, divided them into two groups: those with retinal breaks (group 1) (16 patients, 16 eyes), and those without retinal breaks (group 2) (127 patients, 161 eyes). The group 1 eyes were further divided into three subgroups: those with retinal tears from limited anteroposterior vitreous traction (subgroup A), those with macular holes in an area without posterior vitreous detachment (subgroup B), and those with oval retinal holes anterior to the anteroposterior vitreous traction (subgroup C). Subgroup C comprised most of the eyes in group 1 (10 eyes) and was the only subgroup that we compared with group 2. Significant differences between subgroup C and group 2 were found in terms of the extent of tractional retinal detachment (P = .002) and the degree of preretinal fibrosis (P = .009). These data suggest that large tractional retinal detachments and extensive preretinal fibrosis are significant risk factors for the development of retinal breaks in proliferative diabetic retinopathy.
 ...
PMID:Retinal breaks in diabetic retinopathy: vitreoretinal relationships. 789 63

We studied the development of proliferative diabetic retinopathy (PDR) in Japanese insulin-dependent diabetes mellitus (IDDM). Subjects were 373 patients who were diagnosed as IDDM between 1951 and 1984, before the age of 30 years, and had no PDR at the first visit to the Diabetes Center. Development of PDR was analyzed by Kaplan-Meier's life-table method in relation to the duration of IDDM. The cumulative incidence of PDR was 20% at 15 years of duration of IDDM, 40% at 19 years, and 70% at 29 years. Female patients (n = 233) developed PDR significantly faster than males (n = 140) (P < 0.002). In both sexes, patients with onset of IDDM at 0-8 years showed significantly slower development than patients with the onset at 9-17 (P < 0.0001) and 18-29 years (P < 0.001). Impact of femaleness on the development was the greatest in patients with age at onset of IDDM at 9-17 years (P < 0.005). Analysis according to the calendar year at onset of IDDM and diabetes duration at the first visit to the Diabetes Center did not show any significant influence on the development of PDR. In conclusion, sex and age at onset of IDDM may be associated with increased risk for the development of PDR in relation to the duration of diabetes in Japanese IDDM.
Diabetes Res Clin Pract 1994 Jun
PMID:Development of proliferative retinopathy in Japanese patients with IDDM: Tokyo Women's Medical College Epidemiologic Study. 795 8


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>